Kieren Marr, MD; Chief Executive Officer & Director
Dr. Kieren Marr is the Chief Executive Officer & Director of MycoMed Technologies and a Professor of Medicine, Oncology and Business at Johns Hopkins. An international thought leader on fungal infections and immunosuppressed hosts, she has performed research on preventing infections for over 25 years, with discoveries in both diagnostics and therapeutics. In 2015, Thomson Reuter named Dr. Marr as “One of the World’s Most Influential Scientific Minds”, ranking in top 1% of cited researchers worldwide.
Bradley Spellberg, MD; Director
Dr. Bradley Spellberg, Director, is Professor of Clinical Medicine, Associate Dean for Clinical Affairs and Chief Medical Officer at LA County and University of Southern California. He is an international thought leader on antimicrobials and infections and as co-founder of 3 companies, has helped to translate three molecules currently in clinical trials.
Michael Hannan; Business Director
Michael Hannan is the Chief Business Officer and a Director of MycoMed Technologies. Mick has over 25 years experience developing and commercializing diagnostics and specialty therapeutics with substantial focus in the anti-infective space. Mick has launched several products and companies, and his experience includes leading world wide commercial efforts for Quotient Limited, an Edinburgh, UK-based diagnostics firm; various leadership roles over a ten-year period at GlaxoSmithKline, including R&D Commercial Development, New Product Planning, Marketing, Sales and Licensing & Acquisitions. Mick also has substantial consulting experience helping both new and established companies develop and implement commercial strategy. Mick has his MBA from The Fuqua School of Business at Duke University, and his BA from Colgate University.
Christopher Bentsen M.S, RAC, FRAPS; Scientific Advisory
Christopher Bentsen MS, RAC, FRAPS has over 30 years’ industry experience in diagnostics development, QC/QA, clinical affairs and regulatory affairs. His teams have been successful in obtaining over 20 FDA and CE marked IVD approvals, including FDA clearance of the first fungal antigen based diagnostic assay, which went on to receive a separate biomarker approval from FDA as well.